CureVac will begin production of its candidate coronavirus vaccine at Novartis plants. After the final agreement is signed, Novartis plans to produce up to 50 million doses of the vaccine by the end of 2021, with an additional 200 million doses in 2022. The drug will be manufactured in Austria. Supplies of the vaccine are expected to begin in summer 2021.